Eagle Pharmaceuticals Reports Second Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Francisco Partners to acquire Weave Communications for $650M
Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 34c, Revenues Miss
August 10, 2020 6:53 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.57, $0.34 better than the analyst estimate of $0.23. Revenue for the quarter came in at $41.9 million versus the consensus estimate of $42.28 million.
We had an excellent start to the first half of the year, advancing our exciting pipeline of oncology and critical care products. Our ANDA and orphan drug exclusivity legal... More
